PharmaJet needle-free delivery enhances immune response and provides safety, efficacy, efficiency, and patient comfort for ...

Johnson & Johnson (NYSE: JNJ) today announced results from additional analyses of the Phase 2 DAHLIAS study highlighting improvement in key measures of disease activity and significant IgG reduction ...

04, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to ...

and comprehensive biomarker analyses from the completed Phase 1 clinical trial of MP0317. Posters will be presented at the 2024 Annual Meeting of the Society for Immunotherapy of Cancer (SITC), being ...

The IPG Health agency created 15 portrait-like images to showcase how the lack of diversity in clinical trials costs everyone ...

Exacerbations of the chronic and progressive inflammatory disease bronchiectasis can impact quality of life. Treatment, based ...

Antengene Corporation Limited ('Antengene', SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical ...

Analyst Reni Benjamin of JMP Securities reiterated a Buy rating on BioAtla (BCAB – Research Report), retaining the price target of $5.00.

CT1812 slowed cognitive decline by 95% in Alzheimer’s disease patients with lower levels of plasma p-tau217 in a pre-specified analysis from ...

Poster Hall C Presented by Professor Henkjan Verkade, University of Groningen, Groningen, Netherlands Alagille Syndrome Patient & Physician Fireside Discussion During the meeting, Mirum will host a ...

Infinitopes' lead vaccine candidate ITOP1 is a novel, precision targeted, immunologically durable, "off-the-shelf" cancer vaccine, designed to save lives by preventing disease recurrence in first-line ...